Liquid Biopsy Based NGS in Newly Diagnosed NSCLC
Launched by CHARU AGGARWAL · May 9, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a method called "liquid biopsy" to help doctors make better treatment decisions for patients with a specific type of lung cancer known as metastatic non-squamous non-small cell lung cancer (NSCLC). The trial aims to encourage doctors to order important molecular tests right after a patient is diagnosed, so they can have the results before starting any treatment. This way, doctors can tailor the treatment based on the unique characteristics of the cancer, leading to potentially better outcomes. The study is also interested in understanding what helps or hinders the successful use of this method in clinical practice.
To participate in this trial, you must be diagnosed with metastatic non-squamous NSCLC and have not yet started treatment. Additionally, you need to be seen at one of the participating hospitals in the Lancaster area or nearby locations. Unfortunately, those with incomplete staging information or certain other conditions, such as children and pregnant women, cannot join the study. If you qualify and choose to participate, you'll help researchers learn more about improving lung cancer treatment while also gaining access to valuable testing that can guide your care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants with a histological, or cytological diagnosis of metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) who have not yet received systemic treatment for metastatic disease.
- • Participants must be seen at Lancaster General Health (LGH), Penn Presbyterian Medical Center (PPMC), Penn Medicine Cherry Hill (PMCH), Penn Medicine Princeton Health (PMPH), Penn Medicine Voorhees (PMV) or Penn Medicine Washington Township (PMWT) for mNSq NSCLC.
- Exclusion Criteria:
- • Participants with incomplete staging information.
- • Children, pregnant women, fetuses, neonates, or prisoners are not included in this research study.
About Charu Aggarwal
Charu Aggarwal is a distinguished clinical trial sponsor known for her commitment to advancing medical research and improving patient outcomes. With a strong background in oncology and clinical trial design, she leads initiatives that focus on innovative therapeutic approaches and evidence-based practices. Her leadership fosters collaboration among multidisciplinary teams, ensuring rigorous adherence to regulatory standards and ethical considerations throughout the research process. Charu's expertise not only enhances the quality of clinical trials but also contributes to the development of novel treatments that address unmet medical needs, positioning her as a vital contributor to the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Plainsboro, New Jersey, United States
Philadelphia, Pennsylvania, United States
Lancaster, Pennsylvania, United States
Cherry Hill, New Jersey, United States
Sewell, New Jersey, United States
Voorhees, New Jersey, United States
Patients applied
Trial Officials
Charu Aggarwal, MD, MPH
Principal Investigator
Penn Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported